NeOnc Technologies Holdings, Inc. (NTHI) stock
Close on Nov 13, 2026Market cap $127.35MP/E –Yield –
NeOnc Technologies Holdings, Inc. saw revenue fall 51.8% to $39.99K over fiscal 2025. Free cash flow was -$20.86M. At the latest close the market valued the company at $127.35M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $127.35M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $39.99K
- Net income
- -$43.02M
- EPS, diluted
- -$1.73
- Free cash flow
- -$20.86M
- Book value per share
- -$0.51
- Diluted shares
- 26M
Trading
- Next earnings
- Apr 2, 2027 (estimated, after the close)
- Previous close
- $4.85
- Open
- $4.98
- Day's range
- $4.68 – $5.24
- Volume
- 251,855
- Average volume (20 days)
- 175,770
- 52-week range
- $2.50 – $11.80
- RSI (14 days)
- 78.3
- Volatility (1 year)
- 112.7%
- Relative volume
- 1.37×
On 2 of our idea lists: Insider cluster buys, Insiders buying the dip
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | NTHI | S&P 500 | Difference | NTHI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +89.2% | -3.0% | +92.2 pts | ||
| 3 months | +53.0% | -2.8% | +55.7 pts | ||
| Year to date | -40.6% | +11.5% | −52.1 pts | ||
| 1 year | -45.3% | +13.5% | −58.8 pts |
Three years at a glance
Fiscal years 2023 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases NeOnc Technologies filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated ApprovalUpdate
- Results
- Update
- Update
- Update
About NeOnc Technologies
Pharmaceutical Preparations
NeOnc Technologies is a clinical-stage biopharmaceutical company focused on developing therapies and novel delivery modalities for intracranial malignancies, including primary brain tumors such as glioblastoma and meningioma, as well as secondary brain metastases. The company's pipeline centers on two investigational candidates: NEO100, a purified perillyl alcohol administered intranasally to bypass the blood-brain barrier, and NEO212, an oral and intranasal conjugate of temozolomide and perillyl alcohol. NeOnc currently conducts human clinical trials across targeted patient populations lacking effective alternatives, while also exploring delivery applications for neurodegenerative conditions.
Company profile, executives and historyNeOnc Technologies stock: common questions
What is NeOnc Technologies's stock price?
NTHI closed at $4.91 on Nov 13, 2026, up 1.24% on the day. Over the past 52 weeks it traded between $2.50 and $11.80.
What is NeOnc Technologies's market cap?
NeOnc Technologies was worth $127.35M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is NTHI's P/E ratio?
NeOnc Technologies lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.73), so it has no meaningful P/E ratio.
How much revenue does NeOnc Technologies make?
NeOnc Technologies reported revenue of $39.99K for fiscal 2025, down 51.8% from a year earlier.
Does NeOnc Technologies pay a dividend?
No. NeOnc Technologies has not paid a cash dividend over the last twelve months.
When does NeOnc Technologies report earnings next?
NeOnc Technologies is expected to report Q4 FY2026 results on Apr 2, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has NTHI stock performed over the past year?
Including dividends, NTHI returned -45.3% over the past year, against +13.5% for the S&P 500.
How many NTHI shares are sold short?
1M shares were sold short at the latest FINRA report, 8.89% of the float, or 7.0 days of average trading volume.
Who are NeOnc Technologies's competitors?
Companies most similar to NeOnc Technologies by business, industry and size include KZIA, CNBX, ALT, IXHL, IBO.
See a number that looks wrong?